Mpa-Br Peptide PEG Conjugate for Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to modulating the Tie2/Angiopoietin signaling axis for therapeutic applications are complex and inefficient, particularly in treating vascular leak conditions such as influenza-induced acute lung injury, due to the challenges in purifying and applying Ang1, and existing therapeutics face issues with resistance and specificity.
Innovation Solution
A simpler vasculotide analog, Mpa-Br, is developed by linking a T7 peptide with 3-Mercaptopropionic acid to a PEG tetramer, forming a stable peptide PEG conjugate that activates the Tie2 receptor, stimulating angiogenesis and reducing vascular leak without labile ring structures susceptible to rearrangement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Ang1 is used to activate Tie2 receptor, then angiogenesis is stimulated, but purification and therapeutic application are precluded due to complex nature
Solution Approach 1:
The patent creates simplified copies of Ang1's bioactive structure using synthetic peptides (Tie2-binding peptides) that replicate the essential receptor-activating function without the complexity of the native protein, enabling easy purification and therapeutic application
Solution Approach 2:
The invention extracts only the essential functional elements of Ang1 (the Tie2-binding peptide sequences) from the complex native protein structure, discarding the non-essential portions that complicate purification while retaining therapeutic activity
2Reliability
If large recombinant proteins are engineered to bind and cluster Tie2 receptors, then agonistic action of Ang1 is mimicked, but device complexity increases
Solution Approach 1:
The patent segments the complex recombinant protein structure into smaller, simpler peptide components that individually bind to Tie2 receptors, achieving the same clustering effect with reduced molecular complexity and improved manufacturability
Solution Approach 2:
The invention changes the molecular weight and structural parameters from large recombinant proteins to smaller synthetic peptides, maintaining receptor activation capability while simplifying the overall molecular architecture
3Reliability
If parental vasculotide is used to activate Tie2, then vascular leak is reduced, but labile ring structures are susceptible to rearrangement
Solution Approach 1:
The patent modifies the chemical structure by replacing labile ring structures with stable linear or alternative cyclic configurations, changing the chemical parameters to improve stability while preserving the Tie2 activation and vascular protective functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Mpa-Br effectively stimulates Tie2 phosphorylation, endothelial cell migration, and angiogenesis, providing improved activity over vasculotide in treating diabetic wound healing, allergic diseases, asthma, atopic dermatitis, influenza, and reducing vascular permeability, with enhanced binding and pharmacokinetics.
Implementation Method 1
Mpa-Br effectively stimulates Tie2 phosphorylation
Data Source
Figure 1A
Figure 1B
Figure 2A~2D
AI summary
The present disclosure relates to compounds of Formula (I) which are multimeric forms of a monomeric binding peptide linearly bonded to PEG moieties to form the multimers. The multimeric forms stimulate angiogenesis and promote wound healing. The disclosure also includes pharmaceutical compositions comprising the multimers, including compositions suitable for topical or systemic administration.